Simon Mead
smead2.bsky.social
Prions dementia climbing running dog walking Dad & husband. National Prion Clinic UCLH. Deputy Director @MRC_Prion @UCL NIHR Senior Investigator
👤 Joined on 15 November 2024
88
Followers
3
Following
2
Total Posts
📜 Kullanıcı Geçmişi
- 15 Kas 2024, 21:15
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@smead2.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
As a therapeutic biomarker, seems to me that tau is a measurement of tau. If you did trials, you would see there’s a ton of thought about how to maintain the blind, you’d also see placebo giving rise to IRRs and ARIA. Post hoc data analyses bears this out.
Show PostTotally serious question: have you played a role in these trials as PI or sub-I to witness possible unblinding firsthand and how it plays out? There was an effect on tau:
Show Post
Your main claim against efficacy (rather than pharmacodynamics) seems to be the unblinding argument. Do you see a relationship between rate of infusion reactions and efficacy? These could also unblind, but should have no biological relation to amyloid removal.
Show Post
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab alzforum.org/news/confere... #Alzheimers #dementia #MCI #neurology
Show Post